RaQualia Pharma Inc. AI Stock Analysis
Want to see JP:4579 full AI Analyst Report?
RaQualia Pharma Inc. (4579) AI Stock Analysis
RaQualia Pharma Inc.
(TSE/TYO:4579)
RaQualia earns a moderately above-average score. The strongest support comes from technicals: the shares trade above all key moving averages with positive MACD, signalling a well-established uptrend, though short-term indicators are becoming stretched. Fundamentals are improving but middling — revenue has more than doubled off the 2023 low, margins are exceptionally high, the balance sheet is conservatively equity-funded with falling leverage, and cash flow has turned positive. However, the business remains dependent on lumpy milestone and licensing income, producing volatile margins, swinging cash flow and a modest ~4.6% return on equity. Valuation is the principal drag: a 44x P/E with no dividend leaves little margin for error if the next milestone cycle disappoints.
RaQualia Pharma Inc. (4579) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 19.26B
- Dividend Yield
- ―
- Average Volume (3M)
- 200.50K
- Price to Earnings (P/E)
- 44.4
- Beta (1Y)
- 0.88
- Revenue Growth
- 31.84%
- EPS Growth
- ―
- Country
- Japan
- Employees
- 85
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
RaQualia Pharma Inc. Business Overview & Revenue Model
Company Description
RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegopraza...
RaQualia Pharma Inc. Financial Statement Overview
Summary
RaQualia is in a clear recovery phase. Revenue has nearly doubled from the 2023 trough (¥1.90bn) to ¥4.02bn on a TTM basis, gross margin is outstanding at ~80%, and profitability has returned with ¥590m operating profit and ¥349m net income after losses in 2023 and 2024. The balance sheet is the strongest pillar (Score 68): equity of ¥7.79bn funds ~73% of assets and debt-to-equity has fallen to 0.33 from 0.62. Cash flow has also swung positive (¥746m operating, ¥718m free cash flow) with minimal capex and free cash flow covering ~96% of net income. Offsetting this, earnings and cash generation remain lumpy and milestone-driven — operating cash flow has flipped between large positives and negatives over four years — return on equity is thin at ~4.6%, and leverage is far above the company's historically near-debt-free profile.
Income Statement
57NeutralBalance Sheet
68PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.02B | 3.98B | 3.11B | 1.90B | 2.92B | 2.78B |
| Gross Profit | 3.23B | 3.27B | 2.48B | 1.66B | 2.69B | 2.46B |
| EBITDA | 1.06B | 985.17M | 188.27M | -111.80M | 1.00B | 1.02B |
| Net Income | 348.52M | 273.12M | -495.03M | -323.66M | 723.39M | 755.79M |
Balance Sheet | ||||||
| Total Assets | 10.70B | 10.51B | 9.66B | 6.93B | 6.26B | 5.23B |
| Cash, Cash Equivalents and Short-Term Investments | 4.81B | 3.24B | 3.34B | 3.76B | 3.93B | 2.66B |
| Total Debt | 2.53B | 2.90B | 3.45B | 432.02M | 222.34M | 39.07M |
| Total Liabilities | 2.91B | 3.62B | 4.08B | 809.83M | 760.67M | 446.19M |
| Stockholders Equity | 7.79B | 6.90B | 5.57B | 6.12B | 5.50B | 4.79B |
Cash Flow | ||||||
| Free Cash Flow | 717.72M | -423.98M | 84.24M | -940.80M | 1.45B | 260.61M |
| Operating Cash Flow | 746.39M | -356.63M | 180.94M | -718.60M | 1.48B | 366.03M |
| Investing Cash Flow | -298.84M | 124.32M | -3.67B | -135.37M | -47.65M | -279.25M |
| Financing Cash Flow | 803.03M | 380.26M | 2.98B | 793.45M | -29.56M | -16.44M |
RaQualia Pharma Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4579, the sentiment is Positive. The current price of 740.00 is above the 20-day moving average (MA) of 657.95, above the 50-day MA of 620.96, and above the 200-day MA of 672.09, indicating a bullish trend. The MACD of 32.44 indicates Negative momentum. The RSI at 64.40 is Neutral, neither overbought nor oversold. The STOCH value of 83.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4579.
RaQualia Pharma Inc. Peers Comparison
Overall Rating
JP:456563Neutral
JP:457961Neutral
JP:458851Neutral
JP:458748Neutral
JP:456342Neutral
JP:457141Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 63Neutral | JPY 154.11B | -26.75 | -8.51% | ― | 23.72% | 12.48% | |
| 61Neutral | JPY 18.95B | 44.36 | ― | ― | 31.84% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | JPY 208.84B | -125.84 | ― | ― | 1748.97% | 35.11% | |
| 48Neutral | JPY 144.11B | -47.20 | -5.85% | ― | 14.25% | 50.07% | |
| 42Neutral | JPY 10.31B | -1.77 | -558.92% | ― | 19.67% | 84.06% | |
| 41Neutral | JPY 6.37B | -4.14 | -39.57% | ― | 48.92% | -46.91% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4579 | RaQualia Pharma Inc. | 740.00 | 51.00 | 7.40% | |
| JP:4563 | AnGes | 24.00 | -50.00 | -67.57% | |
| JP:4587 | Peptidream | 1060.00 | -566.00 | -34.81% | |
| JP:4565 | Sosei Group Corporation | 1600.00 | 738.00 | 85.61% | |
| JP:4571 | NanoCarrier Co., Ltd. | 65.00 | -79.00 | -54.86% | |
| JP:4588 | Oncolys BioPharma, Inc. | 6940.00 | 5975.00 | 619.17% |
RaQualia Pharma Inc. Corporate Events
RaQualia Pharma Reports Nine-Month Results Through September 2026
RaQualia Pharma Inc. reported consolidated net sales of ¥2.35 billion for the nine months ended September 30, 2026, up 1.7% from a year earlier. Operating loss narrowed to ¥238 million from ¥344 million, ordinary loss narrowed to ¥261 million from ¥4...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
